AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1336890 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study 1336890 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous calcanean bone loss
Number of subjects: 0
Study 3565727 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diazepam
Number of subjects: 50
Study 3565727 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam
Number of subjects: 50
Study 30997142 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention including motivational interviewing, feedback on sedentary behaviour, goal-setting, environmental modification, self-monitoring, and social support.
Number of subjects: 45
Study 30997142 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention
Number of subjects: 45
Study 30997142 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 45
Study 30153236 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet computer (iPad) with low vision applications and instruction in its use, including accessibility features
Number of subjects: 40
Study 30153236 — intervention group
Group type: COMPARATOR
Intervention: Standard low vision care (Control)
Number of subjects: 40
Study 27461803 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-sedation oxygenation with 100% oxygen
Number of subjects: 60
Study 27461803 — intervention group
Group type: COMPARATOR
Intervention: Room air breathing post-sedation
Number of subjects: 60
Study 27461803 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (100% oxygen and room air)
Number of subjects: 60
Study 24262278 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg once daily) + Ledipasvir (90 mg once daily) + Ribavirin (RBV) for 12 weeks
Number of subjects: 113
Study 24262278 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir + GS-9669 (500 mg once daily) + Ribavirin (RBV) for 12 weeks
Number of subjects: 113
Study 24262278 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir + Ledipasvir + Ribavirin (RBV) for 6 weeks
Number of subjects: 113
Study 24262278 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir + Ledipasvir + Ribavirin (RBV) for 12 weeks (noncirrhotic prior null responders)
Number of subjects: 113
Study 24262278 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir + GS-9669 + Ribavirin (RBV) for 12 weeks (noncirrhotic prior null responders)
Number of subjects: 113
Study 24262278 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir + Ledipasvir + Ribavirin (RBV) for 12 weeks (cirrhotic prior null responders)
Number of subjects: 113
Study 24262278 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir + Ledipasvir without Ribavirin (RBV) for 12 weeks (cirrhotic prior null responders)
Number of subjects: 113
Study 22580654 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin 4mg/24h for 72 hours in addition to open label norepinephrine
Number of subjects: 30
Study 22580654 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine only (Control group)
Number of subjects: 30
Study 20397904 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP with Nd:YAG laser treatment
Number of subjects: 30
Study 20397904 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 30
Study 17656836 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-based cognitive training programme
Number of subjects: 38
Study 17656836 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 15151914 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted risk factor reduction care plan in intervention wards
Number of subjects: 0
Study 15151914 — intervention group
Group type: COMPARATOR
Intervention: Control wards (no targeted risk factor reduction care plan)
Number of subjects: 0
Study 15151914 — intervention group
Group type: COMPARATOR
Intervention: Difference in change between intervention and control wards
Number of subjects: 0
Study 15151914 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls-related injuries
Number of subjects: 0
Study 11782033 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian monitoring and analysis
Number of subjects: 0
Study 11782033 — intervention group
Group type: EXPERIMENTAL
Intervention: Archetypal prior distributions
Number of subjects: 0
Study 11782033 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular reporting of priors, likelihoods, and posterior distributions
Number of subjects: 0
Study 9839827 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin cream (0.025%)
Number of subjects: 40
Study 9839827 — intervention group
Group type: COMPARATOR
Intervention: GTN cream (1.33%)
Number of subjects: 40
Study 9839827 — intervention group
Group type: COMPARATOR
Intervention: GTN cream (1.33%) + Capsaicin cream (0.025%)
Number of subjects: 40
Study 9839827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7527418 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose polymer solution (trial G)
Number of subjects: 4
Study 7527418 — intervention group
Group type: COMPARATOR
Intervention: Placebo (trial C)
Number of subjects: 4
Study 2734422 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory cognitive stressor (mental arithmetic)
Number of subjects: 33
Study 2734422 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring
Number of subjects: 33
Study 2734422 — intervention group
Group type: EXPERIMENTAL
Intervention: Components of verbal competition and loudness of voice
Number of subjects: 33
Study 2734422 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory hyperreactivity
Number of subjects: 33
Study 29754580 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Oriented Pedagogical Project (HOPP) intervention consisting of 45 minutes of physical activity a day for 6-8 months in addition to regular physical education lessons.
Number of subjects: 1173
Study 29754580 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 1173
Study 27306256 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized physical therapy (10 sessions)
Number of subjects: 300
Study 27306256 — intervention group
Group type: COMPARATOR
Intervention: Guideline-based advice (2 sessions)
Number of subjects: 300
Study 26575036 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized epinephrine plus 3% hypertonic saline
Number of subjects: 208
Study 26575036 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus 3% hypertonic saline
Number of subjects: 208
Study 25328957 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated cognitive behaviour therapy (CBT) for PTSD and AUD (IT)
Number of subjects: 62
Study 25328957 — intervention group
Group type: COMPARATOR
Intervention: CBT for AUD plus supportive counselling (AS)
Number of subjects: 62
Study 25328957 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-support (AS)
Number of subjects: 62
Study 21556834 — intervention group
Group type: COMPARATOR
Intervention: Insulin-stimulated glucose uptake in adipose tissue
Number of subjects: 15
Study 21556834 — intervention group
Group type: COMPARATOR
Intervention: Insulin-mediated suppression of lipolysis and adiponectin metabolism
Number of subjects: 15
Study 21556834 — intervention group
Group type: COMPARATOR
Intervention: Hepatic fat content
Number of subjects: 15
Study 21556834 — intervention group
Group type: COMPARATOR
Intervention: Hepatic glucose metabolism
Number of subjects: 15
Study 18085502 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT4) treatment for 6 months
Number of subjects: 60
Study 18085502 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 6 months
Number of subjects: 60
Study 16530965 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful stimulation (venipuncture)
Number of subjects: 40
Study 16530965 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile stimulation (skin disinfection)
Number of subjects: 40
Study 14598874 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine
Number of subjects: 87
Study 14598874 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 87
Study 15572462 — intervention group
Group type: COMPARATOR
Intervention: IVF treatment phases (4 distinct stages)
Number of subjects: 75
Study 15572462 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy (second trimester)
Number of subjects: 75
Study 15572462 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy (third trimester)
Number of subjects: 75
Study 10490250 — intervention group
Group type: EXPERIMENTAL
Intervention: CharcoAid G (CA)
Number of subjects: 60
Study 10490250 — intervention group
Group type: COMPARATOR
Intervention: LiquiChar (LC)
Number of subjects: 60
Study 8942419 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (1000 RE/d) for 30 days
Number of subjects: 36
Study 8942419 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 30 days
Number of subjects: 36
Study 8942419 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD-moderate-severe and COPD-moderate-severe+ex groups
Number of subjects: 36
Study 8942419 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy smokers and COPD-mild patients
Number of subjects: 36
Study 2017645 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g once daily) for 4 weeks
Number of subjects: 30
Study 2017645 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g once daily for 2 weeks) followed by oral amoxicillin (1 g four times a day for 2 weeks)
Number of subjects: 30
Study 2017645 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (2 g once daily) for 4 weeks and Ceftriaxone followed by amoxicillin
Number of subjects: 30
Study 6124760 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetic human insulin (BHI)
Number of subjects: 94
Study 6124760 — intervention group
Group type: COMPARATOR
Intervention: Bovine insulin
Number of subjects: 94
Study 6124760 — intervention group
Group type: COMPARATOR
Intervention: Porcine insulin
Number of subjects: 94
Study 31602579 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete Cytoreduction Risk Score (ICRS) derived from preoperative factors
Number of subjects: 2027
Study 31602579 — intervention group
Group type: EXPERIMENTAL
Intervention: ICRS applied to validation cohort
Number of subjects: 2027
Study 28139512 — intervention group
Group type: EXPERIMENTAL
Intervention: Shikani Optical Stylet (SOS)
Number of subjects: 270
Study 28139512 — intervention group
Group type: COMPARATOR
Intervention: Macintosh Laryngoscope (MLS)
Number of subjects: 270
Study 25734456 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonwoven porous adhesive bandage (NPAB)
Number of subjects: 300
Study 25734456 — intervention group
Group type: COMPARATOR
Intervention: Transparent film adhesive bandage (TFAB)
Number of subjects: 300
Study 25041859 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly adalimumab dosing
Number of subjects: 248
Study 25041859 — intervention group
Group type: COMPARATOR
Intervention: Every other week (EOW) adalimumab dosing
Number of subjects: 248
Study 22241056 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU/kg rHuEpo
Number of subjects: 10
Study 22241056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 18389368 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised resistance exercise
Number of subjects: 242
Study 18389368 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise
Number of subjects: 242
Study 18389368 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 242
Study 17288659 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telecare group
Number of subjects: 30
Study 17288659 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 15145810 — intervention group
Group type: EXPERIMENTAL
Intervention: Local false discovery rate (local FDR) estimation using a mixture model
Number of subjects: 0
Study 15145810 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed mixture model for estimating local FDR
Number of subjects: 0
Study 15145810 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation of the proportion of differentially expressed genes, pFDR, negative predictive values, sensitivity, and specificity
Number of subjects: 0
Study 12536508 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and hyperosmotic glucose solution
Number of subjects: 0
Study 12536508 — intervention group
Group type: COMPARATOR
Intervention: Moist burn ointment (Control)
Number of subjects: 0
Study 9891833 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary prevention (Group I)
Number of subjects: 0
Study 9891833 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary prevention (Group II)
Number of subjects: 0
Study 8296730 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-wire (FW) system
Number of subjects: 602
Study 8296730 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-the-wire (OW) system
Number of subjects: 602
Study 2662674 — intervention group
Group type: EXPERIMENTAL
Intervention: Venoruton
Number of subjects: 15
Study 2662674 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 15
Study 31525187 — intervention group
Group type: EXPERIMENTAL
Intervention: SLATE algorithm
Number of subjects: 1077
Study 31525187 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1077
Study 27905102 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (DAC)
Number of subjects: 52
Study 27905102 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment elevated HbF
Number of subjects: 52
Study 26451070 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D (4000 IU/d)
Number of subjects: 40
Study 26451070 — intervention group
Group type: COMPARATOR
Intervention: Low-dose vitamin D (400 IU/d)
Number of subjects: 40
Study 24079908 — intervention group
Group type: EXPERIMENTAL
Intervention: Storybook intervention (The Tale of Woody's Tonsils)
Number of subjects: 80
Study 24079908 — intervention group
Group type: COMPARATOR
Intervention: Control group (no storybook)
Number of subjects: 80
Study 21266950 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal adiposity, waist circumference (WC), and body mass index (BMI)
Number of subjects: 112
Study 21266950 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity measures
Number of subjects: 112
Study 21056842 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbs extra group (CH) with complementary therapies of Chinese medicine and standard treatment
Number of subjects: 32
Study 21056842 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment only group (ST)
Number of subjects: 32
Study 17384341 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual initiation of bedtime insulin glargine
Number of subjects: 121
Study 17384341 — intervention group
Group type: COMPARATOR
Intervention: Group initiation of bedtime insulin glargine
Number of subjects: 121
Study 17384341 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 121
Study 15872078 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study 15872078 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 11907427 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK506)
Number of subjects: 0
Study 11907427 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 0
Study 10393380 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg/day)
Number of subjects: 31
Study 10393380 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg/day)
Number of subjects: 31
Study 10393380 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 31
Study 7572013 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg buprenorphine (group B)
Number of subjects: 40
Study 7572013 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 40
Study 2322621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.8 g/kg)
Number of subjects: 0
Study 2322621 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 0
Study 2322621 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic beverage
Number of subjects: 0
Study 2322621 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 0
Study 2322621 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic drink
Number of subjects: 0
Study 6894099 — intervention group
Group type: EXPERIMENTAL
Intervention: tolamolol 200 mg
Number of subjects: 22
Study 6894099 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam 10 mg
Number of subjects: 22
Study 6894099 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study 31944502 — intervention group
Group type: EXPERIMENTAL
Intervention: M4 regimen (2R7 H7 Z7 E7 M7 /2R3 H3 M3)
Number of subjects: 1371
Study 31944502 — intervention group
Group type: COMPARATOR
Intervention: Control regimen (2H3 R3 Z3 E3 /4R3 H3)
Number of subjects: 1371
Study 31944502 — intervention group
Group type: EXPERIMENTAL
Intervention: M4-I regimen (2R7 H7 Z7 E7 M7 /2R3 H3 E3 M3)
Number of subjects: 1371
Study 31944502 — intervention group
Group type: EXPERIMENTAL
Intervention: M4-IE regimen (2R7 H7 Z7 E7 M7 /2R3 H3 M3)
Number of subjects: 1371
Study 31944502 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin regimens
Number of subjects: 1371
Study 31944502 — intervention group
Group type: COMPARATOR
Intervention: Control regimen
Number of subjects: 1371
Study 31806605 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 70
Study 31806605 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid/alkylating-agent therapy
Number of subjects: 70
Study 27720359 — intervention group
Group type: EXPERIMENTAL
Intervention: Swiss ball training exercise
Number of subjects: 60
Study 27720359 — intervention group
Group type: EXPERIMENTAL
Intervention: Frenkel exercise
Number of subjects: 60
Study 27720359 — intervention group
Group type: COMPARATOR
Intervention: Control group (no interventions)
Number of subjects: 60
Study 25465978 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg
Number of subjects: 239
Study 25465978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 23433349 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching by medical assistants for 12 months
Number of subjects: 441
Study 23433349 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 441
Study 23433349 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching by medical assistants
Number of subjects: 441
Study 21812663 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Number of subjects: 219
Study 21812663 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab (high-periostin subgroup)
Number of subjects: 219
Study 21812663 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab (low-periostin subgroup)
Number of subjects: 219
Study 19627292 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 0
Study 16769946 — intervention group
Group type: EXPERIMENTAL
Intervention: Scale for the Assessment and Rating of Ataxia (SARA)
Number of subjects: 286
Study 15311105 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (400 mg) and antihypertensive drugs
Number of subjects: 34
Study 15311105 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive drugs only (Control group)
Number of subjects: 34
Study 11707629 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol administration
Number of subjects: 32
Study 11707629 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 32
Study 8988115 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.2% GTN ointment
Number of subjects: 80
Study 8988115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 7691557 — intervention group
Group type: EXPERIMENTAL
Intervention: Topographical mapping of EEG during motor task
Number of subjects: 24
Study 7691557 — intervention group
Group type: COMPARATOR
Intervention: Topographical mapping of EEG during eyes open conditions
Number of subjects: 24
Study 3300569 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolysed wheat ORS
Number of subjects: 78
Study 3300569 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice ORS
Number of subjects: 78
Study 3300569 — intervention group
Group type: COMPARATOR
Intervention: Glucose ORS
Number of subjects: 78
Study 30451888 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavoglurant (up to 100 mg bid for up to 34 months)
Number of subjects: 267
Study 30451888 — intervention group
Group type: COMPARATOR
Intervention: Placebo (from core studies)
Number of subjects: 267
Study 26566638 — intervention group
Group type: EXPERIMENTAL
Intervention: Tönnis classification assessment by three orthopaedic surgeons
Number of subjects: 61
Study 24920884 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (fluticasone 1,000 μg + salmeterol 100 μg/day)
Number of subjects: 237
Study 24920884 — intervention group
Group type: COMPARATOR
Intervention: Medium dose (fluticasone 500 μg + salmeterol 100 μg/day)
Number of subjects: 237
Study 22383318 — intervention group
Group type: EXPERIMENTAL
Intervention: Symax(TM) uncemented stem
Number of subjects: 49
Study 22383318 — intervention group
Group type: COMPARATOR
Intervention: Omnifit(®) uncemented stem
Number of subjects: 49
Study 20502447 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancrelipase (72,000 lipase units per meal; 36,000 per snack)
Number of subjects: 54
Study 20502447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 20502447 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancrelipase
Number of subjects: 54
Study 18700898 — intervention group
Group type: EXPERIMENTAL
Intervention: Parnaparin-MMX (70, 140, and 210 mg once daily) for 8 weeks
Number of subjects: 10
Study 15191507 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg)
Number of subjects: 18
Study 15191507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12370870 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight-supported treadmill training (BWSTT)
Number of subjects: 24
Study 12370870 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (PT)
Number of subjects: 24